scholarly journals 18F-FDG PET Database of Longitudinally Confirmed Healthy Elderly Individuals Improves Detection of Mild Cognitive Impairment and Alzheimer's Disease

2007 ◽  
Vol 48 (7) ◽  
pp. 1129-1134 ◽  
Author(s):  
L. Mosconi ◽  
W. H. Tsui ◽  
A. Pupi ◽  
S. De Santi ◽  
A. Drzezga ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Elderly Individuals ◽  
Healthy Elderly ◽  
18F Fdg

scholarly journals Analysis of the posterior cingulate cortex with [ 18 F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer's disease: Correlations and differences between the two methods

2015 ◽  
Vol 9 (4) ◽  
pp. 385-393 ◽  
Author(s):  
Artur M.N. Coutinho ◽  
Fábio H.G. Porto ◽  
Poliana F. Zampieri ◽  
Maria C. Otaduy ◽  
Tíbor R. Perroco ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Cingulate Cortex ◽  
Posterior Cingulate Cortex ◽  
Cognitively Normal ◽  
Posterior Cingulate ◽  
18F Fdg

ABSTRACT Reduction of regional brain glucose metabolism (rBGM) measured by [18F]FDG-PET in the posterior cingulate cortex (PCC) has been associated with a higher conversion rate from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Magnetic Resonance Spectroscopy (MRS) is a potential biomarker that has disclosed Naa/mI reductions within the PCC in both MCI and AD. Studies investigating the relationships between the two modalities are scarce. OBJECTIVE To evaluate differences and possible correlations between the findings of rBGM and NAA/mI in the PCC of individuals with AD, MCI and of cognitively normal volunteers. METHODS Patients diagnosed with AD (N=32) or MCI (N=27) and cognitively normal older adults (CG, N=28), were submitted to [18F]FDG-PET and MRS to analyze the PCC. The two methods were compared and possible correlations between the modalities were investigated. RESULTS The AD group exhibited rBGM reduction in the PCC when compared to the CG but not in the MCI group. MRS revealed lower NAA/mI values in the AD group compared to the CG but not in the MCI group. A positive correlation between rBGM and NAA/mI in the PCC was found. NAA/mI reduction in the PCC differentiated AD patients from control subjects with an area under the ROC curve of 0.70, while [18F]FDG-PET yielded a value of 0.93. CONCLUSION rBGM and Naa/mI in the PCC were positively correlated in patients with MCI and AD. [18F]FDG-PET had greater accuracy than MRS for discriminating AD patients from controls.

18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage

2017 ◽  
Vol 44 (12) ◽  
pp. 2073-2083 ◽  
Author(s):  
Silvia Morbelli ◽  
Matteo Bauckneht ◽  
Dario Arnaldi ◽  
Agnese Picco ◽  
Matteo Pardini ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
18F Fdg

P2-023: MILD COGNITIVE IMPAIRMENT WITH A HIGH RISK OF PROGRESSION TO ALZHEIMER'S DISEASE DEMENTIA (MCI-HR-AD): EFFECT OF SOUVENAID® TREATMENT ON COGNITION AND 18F-FDG PET SCANS

2006 ◽  
Vol 14 (7S_Part_12) ◽  
pp. P674-P675
Author(s):  
Maria Sagrario Manzano Palomo ◽  
Belen Anaya Caravaca ◽  
Maria Angeles Balsa Breton ◽  
Sergio Muñiz Castrillo ◽  
Maria Asuncion De La Morena Vicente ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Fdg Pet ◽  
Risk Of Progression ◽  
18F Fdg ◽  
Pet Scans ◽  
Alzheimer’S Disease Dementia

Multimodal Classification of Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: Integrated 18F-FDG PET and DTI Study

2021 ◽  
pp. 1-13
Author(s):  
Weihua Li ◽  
Zhilian Zhao ◽  
Min Liu ◽  
Shaozhen Yan ◽  
Yanhong An ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Classification Performance ◽  
Amnestic Mild Cognitive Impairment ◽  
Healthy Controls ◽  
Characteristic Analysis ◽  
18F Fdg

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline and memory impairment. Amnestic mild cognitive impairment (aMCI) is the intermediate stage between normal cognitive aging and early dementia caused by AD. It can be challenging to differentiate aMCI patients from healthy controls (HC) and mild AD patients. Objective: To validate whether the combination of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and diffusion tensor imaging (DTI) will improve classification performance compared with that based on a single modality. Methods: A total of thirty patients with AD, sixty patients with aMCI, and fifty healthy controls were included. AD was diagnosed according to the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable. aMCI diagnosis was based on Petersen’s criteria. The 18F-FDG PET and DTI measures were each used separately or in combination to evaluate sensitivity, specificity, and accuracy for differentiating HC, aMCI, and AD using receiver operating characteristic analysis together with binary logistic regression. The rate of accuracy was based on the area under the curve (AUC). Results: For classifying AD from HC, we achieve an AUC of 0.96 when combining two modalities of biomarkers and 0.93 when using 18F-FDG PET individually. For classifying aMCI from HC, we achieve an AUC of 0.79 and 0.76 using the best individual modality of biomarkers. Conclusion: Our results show that the combination of two modalities improves classification performance, compared with that using any individual modality.

P1-254: 18F-FDG PET/CT ON THE DIFFERENTIAL DIAGNOSIS BETWEEN MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE

2014 ◽  
Vol 10 ◽  
pp. P400-P400
Author(s):  
Jonas Jardim de Paula ◽  
Maria Aparecida Bicalho ◽  
Fernanda Carvalho ◽  
Marcelo Mamede ◽  
Laiss Bertola ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Differential Diagnosis ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

P1-076: Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, mild cognitive impairment, and healthy controls

2009 ◽  
Vol 5 (4S_Part_7) ◽  
pp. P194-P194
Author(s):  
Davangere P. Devanand ◽  
Arthur Mikhno ◽  
Gregory H. Pelton ◽  
Katrina Cuasay ◽  
J.S. Dileep Kumar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Healthy Controls ◽  
Pittsburgh Compound B ◽  
18F Fdg

scholarly journals IC-P-030: Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, Mild Cognitive Impairment and healthy controls

2009 ◽  
Vol 5 (4S_Part_1) ◽  
pp. P16-P17
Author(s):  
Davangere P. Devanand ◽  
Arthur Mikhno ◽  
Gregory H. Pelton ◽  
Katrina Cuasay ◽  
J.S. Dileep Kumar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Fdg Pet ◽  
Healthy Controls ◽  
Pittsburgh Compound B ◽  
18F Fdg
Sign in / Sign up

Export Citation Format

Share Document